News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CEL-SCI (CVM) Reports 146 Patients Enrolled In Its Phase 3 Immunotherapy Head And Neck Cancer Trial



2/27/2014 9:55:57 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT:CVM) today reported accelerating progress in patient enrollment in the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection). Approximately 146 patients have been enrolled in the Phase III study to date.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES